Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165941 · ClinicalTrials.gov registry record · Phase 1
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
A Phase 1 study of Brain Tumor Adult, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04165941 is a Phase 1 study of Brain Tumor Adult that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 22 participants, below the 76-participant average among 6 other Brain Tumor Adult trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04165941, a Phase 1 study of Brain Tumor Adult, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide (TMZ).
Conditions Studied
Interventions
- BIOLOGICAL DRI cell therapy
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04165941
The ClinicalTrials.gov registry entry for NCT04165941 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 6 other Brain Tumor Adult trials with a reported enrollment target (71% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor Adult appearing as the primary indexed condition, and to 1 intervention - of which DRI cell therapy is the first listed.
NCT04165941 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT04165941 about?
NCT04165941 is a clinical study titled "Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma". This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide (TMZ).
What is the current status of trial NCT04165941?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-02-11. Estimated completion is 2026-12-31.
What conditions does trial NCT04165941 study?
This clinical trial studies the following conditions: Brain Tumor Adult.
What interventions are being tested in trial NCT04165941?
The interventions under investigation include: DRI cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04165941?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04165941 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
-
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
RECRUITING
-
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
RECRUITING · Phase 4
-
A Study of Cognitive Changes in Patients Receiving Brain Radiation
ACTIVE NOT RECRUITING
-
Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.